Delcath Systems (NASDAQ:DCTH) Hits New 1-Year High – Time to Buy?

Delcath Systems, Inc. (NASDAQ:DCTH)’s stock price hit a new 52-week high during mid-day trading on Thursday . The company traded as high as $15.80 and last traded at $15.81, with a volume of 298390 shares traded. The stock had previously closed at $15.21.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on the stock. Canaccord Genuity Group reiterated a “buy” rating and issued a $21.00 price objective on shares of Delcath Systems in a research report on Friday, October 18th. Craig Hallum boosted their price target on shares of Delcath Systems from $18.00 to $21.00 and gave the stock a “buy” rating in a research report on Friday, January 17th. HC Wainwright restated a “buy” rating and set a $22.00 price target on shares of Delcath Systems in a research report on Tuesday, January 14th. Stephens restated a “buy” rating on shares of Delcath Systems in a research report on Friday, October 18th. Finally, StockNews.com upgraded shares of Delcath Systems from a “sell” rating to a “hold” rating in a research report on Friday, October 25th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Delcath Systems currently has a consensus rating of “Moderate Buy” and a consensus price target of $22.25.

Delcath Systems Trading Up 6.0 %

The business’s fifty day moving average is $11.79 and its 200 day moving average is $10.08. The firm has a market capitalization of $515.68 million, a P/E ratio of -11.95 and a beta of 0.87.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in DCTH. Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Delcath Systems in the third quarter worth approximately $102,000. Barclays PLC purchased a new position in shares of Delcath Systems in the third quarter worth approximately $104,000. Jane Street Group LLC purchased a new position in shares of Delcath Systems in the third quarter worth approximately $110,000. Riverwater Partners LLC purchased a new position in shares of Delcath Systems in the third quarter worth approximately $161,000. Finally, Baader Bank Aktiengesellschaft purchased a new position in shares of Delcath Systems in the fourth quarter worth approximately $204,000. 61.12% of the stock is owned by hedge funds and other institutional investors.

Delcath Systems Company Profile

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.